Presentation is loading. Please wait.

Presentation is loading. Please wait.

Study Guide for Calcium and Phosphate Metabolism The most important first messengers for Dental Biochemistry include parathyroid hormone, calcitonin, insulin,

Similar presentations

Presentation on theme: "Study Guide for Calcium and Phosphate Metabolism The most important first messengers for Dental Biochemistry include parathyroid hormone, calcitonin, insulin,"— Presentation transcript:

1 Study Guide for Calcium and Phosphate Metabolism The most important first messengers for Dental Biochemistry include parathyroid hormone, calcitonin, insulin, and glucagon Name common second messengers and how they operate Define calcium balance Describe the properties and mechanism of action of parathyroid hormone (PTH) including G-protein function Review the composition of bone, and know what bone mineral is What are the two main functions of parathyroid hormone in kidney? Describe the metabolic activation of vitamin D What are the actions of vitamin D? What is osteomalacia? Rickets? Hyperparathyroidism? Pseudohypoparathyroidism? What is osteoporosis? Describe physiological ways to establish and maintain maximum bone density What foods are good sources of dietary calcium?

2 Elements of the Body (Table 2-1)

3 Overview Calcium (Ca 2+ )CharacteristicPhosphate (HPO 4 2- ) 99%Body total in bone/teeth85% 1.3 mM (ionized)Plasma concentration of ionic form 1.3 mM Carefully controlledNormal variation of ionic form Within 50% 10 4 -10 5 [extracellular]/[intra- cellular] 10 Cell signaling and 2 nd messenger Neurotransmitter and hormone release Exocytosis of proteins Muscle contraction Blood clotting Biomineralization Regulatory roles Important conclusion, calcium is an important regulator Nil

4 Regulation of Calcium Metabolism Minerals; serum concentration –Calcium (Ca 2+ ); 2.2-2.6 mM (total) –Phosphate (HPO 4 2- ); 0.7-1.4 mM –Magnesium (Mg 2+ ); 0.8-1.2 mM Organ systems that play an import role in Ca 2+ metabolism –Skeleton –GI tract –Kidney Calcitropic Hormones –Parathyroid hormone (PTH) –Calcitonin (CT) –Vitamin D (1,25 dihydroxycholecalciferol) –Parathyroid hormone related protein (PTHrP)

5 Sutherland Second Messenger Hypothesis Understand this key concept

6 Second Messengers Fig. 19-4

7 More Second Messenger

8 Three Forms of Circulating Ca 2+

9 Calcium Balance Intake = output Negative calcium balance: Output > intake –Neg Ca 2+ balance leads to osteoporosis Positive calcium balance: Intake > output –Occurs during growth Calcium is essential, we can’t synthesize it

10 Calcium and the Cell Translocation across the plasma membrane Translocation across the ER and mitochondrion; Ca 2+ ATPase in ER and plasma membrane

11 Anatomy and Feedback Inhibition

12 Parathyroid Hormone Structure Synthesized in the 4 para- thyroid glands PreProPTH 115 aa precursor giving a 90 aa prohormone Cleaved at -6/-7 84 residues in the mature peptide Regulator of Ca 2+ homeostasis

13 Parathyroid Hormone Biosynthesis

14 Regulation of PTH Secretion and Biosynthesis Extracellular Ca 2+ regulates secretion of PTH –Low Ca 2+ increases –High Ca 2+ decreases Ca 2+ also regulates transcription High levels of 1,25 dihydroxyvitamin D3 inhibit transcription

15 Calcium Sensing Receptor (CaSR) Parathyroid chief cells contain a Ca 2+ sensing receptor (CaSR) –7 transmembrane segments (We will see a lot of 7 TM receptors) –mM affinity for Ca 2+ –GPCR of the G PLC and G I varieties Generates inositol 1,4, 5-trisphosphate which  increases intracellular Ca 2+ There are two paradoxes –The receptor responds to decreasing concentrations of agonist –Low extracellular Ca 2+ increases intracellular Ca 2+ –Also found in thyroid C cells (calcitonin), kidney, and brain

16 Circulating Forms of PTH Intact, active PTH of 84 aa Inactive carboxyterminal fragments lack the 1-34 active domain PTH t 1/2 (half life) is 2-3 min Liver (2/3 rds ) and kidney (1/3 rd ) are major sites of fragmentation

17 Actions of Parathyroid Hormone Fine tunes Ca 2+ levels in blood –It increases Ca 2+ –It decreases P i Parathyroid hormone acts directly on bone to stimulate resorption and release of Ca 2+ into the extracellular space (slow) –Gs protein-coupled receptors in osteoblasts increase cAMP and activate PKA –Inhibits osteoblast function –This occurs when PTH is secreted continuously; the opposite occurs when it is given once daily by injection Two effects in kidney –Parathyroid hormone acts directly on kidney to increase calcium reabsorption and phosphate excretion (rapid) Gs protein-coupled receptors Parathyroid hormone acts on distal tubule Calcitonin inhibits –Stimulates transcription of 1-alpha hydroxylase for Vitamin D activation in kidney Vitamin D increases calcium and phosphate absorption

18 Parathyroid Hormone Receptor 7 TM GPCR

19 G-Protein Cycle (Fig. 19-10)

20 Regulation of Adenylyl Cyclase (Fig. 19-11) 7 and 12 TM segments

21 Cyclic AMP Metabolism (Fig. 19-12) Know each step involved in the generation of cAMP by PTH (words, not structures)

22 Bone Inorganic (67%) –Hydroxyapatite 3 Ca 10 (PO 4 ) 6 (OH) 2 –There is some amorphous calcium phosphate Organic (33%) component is called osteoid –Type I collagen (28%) –Non-collagen structural proteins (5%) Proteoglycans Sialoproteins Gla-containing proteins (gamma carboxyglutamate) Phosphoproteins Bone specific proteins: osteocalcin, osteonectin –Growth factors and cytokines (Trace) Bone undergoes continuous turnover or remodeling throughout life –About 20% of bone is undergoing remodeling at any one time

23 Bone Composition

24 Calcium and the Skeleton A, absorption is stimulated by Vit D; S, secretion GF, glomerular filtration; TR, tubular reabsorption of Ca 2+ is stimulated by PTH

25 Osteoblast and Osteoclast Function Osteoblasts Bone formation Synthesis of matrix proteins –Type I collagen –Osteocalcin –Others Mineralization Activation of osteoclasts via RANKL production Osteoclasts Bone resorption –Degradation of proteins by enzymes –Acidification RANK is activated by RANKL, and this leads to cells differentiation to osteoclasts

26 Bone Remodeling Osteoclasts dissolve bone –Large multinucleated giant cells Osteoblasts produce bone –Have receptors for PTH, CT, Vitamin D, cytokines, and growth factors –Main product is collagen When osteoblasts become encased in bone, they become osteocytes

27 PTH and Osteoblastogenesis

28 Osteoclast Mediated Bone Resorption

29 Osteoclastogenesis: RANKL, RANK, and OPG Osteoblasts activate osteoclasts, formation of a multinuclear cell The molecular participants in this pathway are the membrane- associated protein named RANKL (receptor activator of nuclear factor kappa B ligand,) a member of the tumor necrosis factor family of cytokines Its cognate receptor is RANK; TRAF, TNF receptor associated factors –Mediates activation of NF-kappa-B by unknown mechanism OPG (osteoprotegerin) is a soluble "decoy" receptor for RANKL RANKL is expressed on the surface of osteoblastic stromal cells By binding to RANK, its receptor, on osteoclast precursors, RANKL enhances their recruitment into the osteoclastogenesis pathway in the physiology of bone metabolism RANKL also activates mature osteoclasts to resorb bone RANKL is a factor through which osteoblasts regulate osteoclasts, and bone formation is coupled to bone resorption


31 Osteoclastogenesis

32 PTH and Kidney PTH acts on the distal tubule

33 Calcitonin Product of parafollicular C cells of the thyroid 32 aa Inhibits osteoclast mediated bone resorption –This decreases serum Ca 2+ Promotes renal excretion of Ca 2+

34 Calcitonin Probably not essential for human survival Potential treatment for hypercalcemia 7 transmembrane segment receptor Stimulates cAMP production in bone and kidney

35 Vitamin D Metabolism

36 Transport and Metabolic Sequence of Activation of Vitamin D

37 Proposed Mechanism of Action of 1,25-DihydroxyD 3 in Intestine

38 Vitamin D-dependent Ca 2+ Absorption Duodenum>jejunun>ileum Absorption is greater at low pH –The pH of the stomach is about 2 –Peak absorption at the beginning of the duodenum

39 Vitamin D Deficiency: Rickets Inadequate intake and absence of sunlight The most prominent clinical effect of Vitamin D deficiency is osteomalacia, or the defective mineralization of the bone matrix Osteoblasts contain the vitamin D receptor Vitamin D deficiency in children produces rickets A deficiency of renal 1α-hydroxylase produces vitamin D-resistant rickets –Sex linked gene on the X chromosome –Renal tubular defect of phosphate resorption –Teeth may be hypoplastic and eruption may be retarded

40 Rickets

41 Vitamin D-Resistant Rickets Above: Hypoplastic teeth Below: Minimal caries can produce pulpitis; periapical abscesses are thus common Lack 1-hydroxylase in kidney Rx: Respond well to 1, 25- dihydroxyD 3

42 PTHrP; Parathyroid Hormone related Protein It is synthesized as 3 isoforms as a result of alternative splicing (139, 141, 173 aa) Can activate the PTH receptor Plays a physiological role in lactation, possibly as a hormone for the mobilization and/or transfer of calcium to the milk May be important in fetal development May play a role in the development of hypercalcemia of malignancy –Some lung cancers are associated with hypercalcemia –Other cancers can be associated with hypercalcemia

43 PTHrP; Parathyroid Related Protein

44 Causes of Hypocalcemia HypoparathyroidNonparathyroidPTH Resistance PostoperativeVitamin D deficiency Pseudo- hypoparathyroidism IdiopathicMalabsorption Post radiationLiver disease Kidney disease Vitamin D resistance

45 Sequence of Adjustments to Hypocalcemia

46 Pseudohypoparathyroidism Symptoms and signs –Hypocalcemia –Hyperphosphatemia –Characteristic physical appearance: short stature, round face, short thick neck, obesity, shortening of the metacarpals –Autosomal dominant Resistance to parathyroid hormone The patients have normal parathyroid glands, but they fail to respond to parathyroid hormone or PTH injections The rise in urinary cAMP after parathyroid hormone fails to occur The cause of the disease is a 50% deficiency of Gs in all cells Symptoms begin in children of about 8 years –Tetany and seizures –Hypoplasia of dentin or enamel and delay or absence of eruption occurs in 50% of people with the disorder Rx: vitamin D and calcium

47 Pseudohypoparathyroidism Elfin facies, short stature, enamel hypoplasia

48 Signs and Symptoms of Hypercalcemia Neurologic –Lethargy, drowsiness, depression, confusion –Can lead to coma and death Neuromuscular –Muscle weakness, hyptonia, decreased reflexes Cardiac –Arrhythmias Bone –Ache, pain, fracture

49 Causes of Hypercalcemia CommonUncommon Malignant disease, e.g. some lung cancers Renal failure HyperparathyroidismSarcoidosis Vitamin D toxicity (excessive intake) Multiple myeloma

50 Causes of Hypercalcemia Primary hyperparathyroidism –Most people are asymptomatic –Classically affects skeleton, kidneys, and GI tract Triad of complaints: bones, stones, and abdominal groans –Renal stones are most common single presenting complaint –Usually due to an adenoma (tumor)

51 Hyperparathyroidism The disorder is characterized by hypercalcemia, hypercalcuria, hypophosphatemia, and hyperphosphaturia Parathyroid hormone causes phosphaturia and a decrease in serum phosphate Calcium rises and it is also secreted in the urine Most common complication are renal stones made of calcium phosphate –Stone chemistries: calcium, phosphate, urate Most serious complication is the deposition of calcium in the kidney tubules resulting in impaired renal function

52 Primary Hyperparathyroidism Calcium excretion > calcium intake Large regions of bone are replaced by connective tissue Two lesions: maxilla and forehead

53 Hyperparathyroidism Left: Giant Cell Granuloma Right: Loss of lamina dura, pathognomonic oral change in hyperparathyroidism

54 Lamina Dura Tooth sockets are bounded by a thin radiopaque layer of dense bone Lamina dura: “hard layer”

55 Congenital Hypoparathyroidism Hypoplasia of the teeth, shortened roots, and retarded eruption

56 Hypercalcemia of Malignancy Treatment improves quality of life when Ca 2+ is elevated but not yet life threatening Treat with bisphosphonates –Inhibits osteoclastic activity When serum Ca 2+ > 3.00 mM treat with NaCl IV

57 Bisphosphonates

58 Osteoporosis Osteoporosis is characterized by a significant reduction in bone mineral density compared with age- and sex-matched norms There is a decrease in both bone mineral and bone matrix Osteoporosis is the most common metabolic bone disease Affects 20 million Americans and leads to 1.3 million fractures in the US per year Women lose 50% of their trabecular bone and 30 % of their cortical bone 30% of all postmenapausal women will sustain an osteoporotic fracture as will 1/6 th of all men The cost of health care and lost productivity is $14 billion in the US annually

59 Normal and Osteoporotic Bone

60 Factors that Affect Peak Bone Mass Gender (M>F), males have greater PBM than females Race (Blacks >Whites) Genetics (osteoporosis runs in families and this may be the predominant factor) –Estrogen receptor gene –Type I collagen gene –Vitamin D receptor gene Gonadal steroids (estrogen and testosterone increase bone mass) Growth hormone (increases bone mass) Calcium intake (supplements work) Exercise (increases bone mass)

61 Sequelae of Osteoporosis

62 Osteo- porosis

63 Bone Density as a Function of Age

64 FDA Approved Rx’s for Osteoporosis Bisphosphonates (alendronate and risedronate), calcitonin, estrogens, parathyroid hormone and raloxifene are approved by the US Food and Drug Administration (FDA) for the prevention and/or treatment of osteoporosis The bisphosphonates (alendronate and risedronate), calcitonin, estrogens and raloxifene affect the bone remodeling cycle and are classified as anti-resorptive medications Teriparatide, a form of parathyroid hormone, is a newly approved osteoporosis medication. It is the first osteoporosis medication to increase the rate of bone formation in the bone remodeling cycle

65 Treatments (Continued) Exercise, activity Calcium intake should be 1000-1500 mg/day –Postmenapausal women take in less than 500 mg/day –Males and females should take in 1000-1500 mg/day –All adults greater than 65 years should take 1500 mg/day –Three glasses of milk or three cups of yogurt per day provide 1000-1500 mg/day Estrogen treatment –Estrogen inhibits osteoclastic activity –Bone density increases 3-5% per year for the first three years after menopause –This therapy needs to be individualized Estrogen may increase the incidence of breast cancer, heart attacks, stroke, blood clots That it may exacerbate cardiovascular disease is controversial –All the data are not in yet, and estrogen treatment is under review; for more information go to

66 Treatments (Continued) Raloxifene (Brand name Evista) is a selective estrogen receptor modulator Decreases in estrogen levels after menopause lead to increases in bone resorption and bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation is inadequate to offset resorptive losses. This imbalance between resorption and formation is related to loss of estrogen, and may also involve age-related impairment of osteoblasts or their precursors Raloxifene reduces resorption of bone and decreases overall bone turnover. These effects on bone are manifested as increases in bone mineral density (BMD) Raloxifene’s biological actions, like those of estrogen, are mediated through binding to estrogen receptors. This binding results in the modulation of expression of multiple estrogen-regulated genes in different tissues

67 Treatments (Continued) Bisphosphonates inhibit osteroclasts –Alendronate (Brand name Fosamax) –Risedronate (Brand name Actonel) Calcitonin (Brand name Miacalcin ) –From salmon –Given intranasaly –Probably least effective Rx Vitamin D –Most Americans consume less than recommended amount –800 IU per day seems safe and not enough to cause vitamin D toxicity

68 Treatments (Continued) Parathyroid hormone (Brand name Forteo) –Teriparatide, a form of parathyroid hormone, is approved for the treatment of osteoporosis in postmenopausal women and men who are at high risk for a fracture –Chronically elevated PTH leads to bone loss; however, intermittent PTH (once daily bolus injection) leads to new bone synthesis –Must be injected daily, a major disadvantage –Cost about $7000 per year Future Rx’s Sodium fluoride –Considered a possibility for years –Adoption seems unlikely Strontium ranelate –NEJM 350 (2004) 459-468.

69 Calcium Content of Foods /SR16/wtrank/wt_rank.html /SR16/wtrank/wt_rank.html

70 Selected Web Sites

71 Properties of Parathyroid Hormone It is a small protein hormone It acts on its 7 transmembrane segment receptor –Gs protein-coupled receptors in osteoblasts increase [cAMP] and activates protein kinase A –Parathyroid hormone acts directly on bone to stimulate resorption and release of Ca 2+ into the extracellular space (slow) –Parathyroid hormone acts directly on kidney to increase calcium reabsorption and phosphate excretion (rapid) –Parathyroid hormone acts on distal tubule and stimulates calcium resorption –Parathyroid hormone stimulates transcription of 1-alpha hydroxylase for vitamin D activation in kidney Know how 7 transmembrane segment receptors activate or inhibit adenylyl cyclase via the G-protein cycle Know the pathway for the formation of active vitamin D

72 Transport and Metabolic Sequence of Activation of Vitamin D

73 PTH Biosynthesis PTH is co-secreted with chromogranin A, a protein; significance unknown

74 Sequence of Adjustments to Hypocalcemia

Download ppt "Study Guide for Calcium and Phosphate Metabolism The most important first messengers for Dental Biochemistry include parathyroid hormone, calcitonin, insulin,"

Similar presentations

Ads by Google